TY  - JOUR
A1  - Bulycheva, Ekaterina
A1  - Rauner, Martina
A1  - Medyouf, Hind
A1  - Theurl, Igor
A1  - Bornhäuser, Martin
A1  - Hofbauer, Lorenz Christian
A1  - Platzbecker, Uwe
T1  - Myelodysplasia is in the niche : novel concepts and emerging therapies
T2  - Leukemia
N2  - Myelodysplastic syndromes (MDSs) represent clonal disorders mainly of the elderly that are characterized by ineffective hematopoiesis and an increased risk of transformation into acute myeloid leukemia. The pathogenesis of MDS is thought to evolve from accumulation and selection of specific genetic or epigenetic events. Emerging evidence indicates that MDS is not solely a hematopoietic disease but rather affects the entire bone marrow microenvironment, including bone metabolism. Many of these cells, in particular mesenchymal stem and progenitor cells (MSPCs) and osteoblasts, express a number of adhesion molecules and secreted factors that regulate blood regeneration throughout life by contributing to hematopoietic stem and progenitor cell (HSPC) maintenance, self-renewal and differentiation. Several endocrine factors, such as erythropoietin, parathyroid hormone and estrogens, as well as deranged iron metabolism modulate these processes. Thus, interactions between MSPC and HSPC contribute to the pathogenesis of MDS and associated pathologies. A detailed understanding of these mechanisms may help to define novel targets for diagnosis and possibly therapy. In this review, we will discuss the scientific rationale of "osteohematology" as an emerging research field in MDS and outline clinical implications.
Y1  - 2014
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/37309
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-373093
SN  - 1476-5551
SN  - 0887-6924
N1  - Copyright © 2015 Macmillan Publishers Limited This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
VL  - 29
IS  - 2
SP  - 259
EP  - 268
PB  - Nature Publ. Group
CY  - Basingstoke
ER  -